Viking Therapeutics, Inc.
$37.81
The Read: VKTX shares have historically declined sharply on concerns over VK2735's tolerability and competitive differentiation against dominant GLP-1 drugs, but rallied on advancing its Phase 3 VANQUISH obesity trials and positive Phase 2 efficacy data.
Price
Overlays
Panel
VKTX
Hover to view data
No Data